About our companyCAR-T Therapy Overview
Indications of CAR-T
● B-cell acute lymphoblastic leukemia
● Multiple myeloma
● Chronic lymphocytic leukemia
● Non-Hodgkin lymphoma
● Diffuse large B-cell lymphoma
● SLE（Systemic Lupus Erythematosus）
Excellent CAR-T clinical performance
Indications for CD19+20CAR-T: Patients with B-cell non Hodgkin's lymphoma
One month CR rate |
One month PR rate |
One month OR rate |
CRS≥3 |
CRES≥3 |
71.95%（59/82） |
25.6（21/82） |
97.55（80/82） |
12.19%（10/82） |
0 |
Indications for CD19+22CAR-T: Treatment of CD19 relapsed and refractory acute B-lymphocytic leukemia patients
One month CR rate |
One month PR rate |
One month OR rate |
CRS≥3 |
CRES≥3 |
92.1%（35/38） |
7.9%（3/38） |
100%（38/38） |
15.79%（6/38） |
0 |
Indications for BCMACAR-T: Treatment of relapsed and refractory multiple myeloma
One month CR rate |
One month PR rate |
One month OR rate |
CRS≥3 |
CRES≥3 |
72.41%（21/29） |
27.59%（8/29） |
100%（29/29） |
6.9%（2/29） |
0 |
Why Choose Us?
Our Advantages
● Personalized Treatment: We customize CAR-T therapy for each patient, ensuring targeted and effective treatment.
● Diverse Targeting Options: Our CAR-T products offer a wide range of target options, including CD7, CD19, CD20, CD22, and BCMA, providing the advantage of personalized treatment options for patients.
● Cutting-edge Technology: Our CAR-T therapy utilizes the latest advancements in genetic engineering and immunotherapy.
● High cost-effectiveness: Compared to other products, we offer a superior balance between quality assurance and competitive pricing.
● Clinical Expertise: Backed by a team of experienced clinicians and researchers, we deliver high-quality care and support throughout the treatment process.
● Comprehensive Approach: We offer comprehensive care, from patient evaluation to therapy administration and follow-up, ensuring optimal outcomes.